Institute of Clinical Research (India) has managed to provide placements for the entire batch of students passing out this year. The students have been placed in leading multinational and Fortune 500 companies.
Almost 202 companies like Pfizer, Novartis, Sanofi, Quintiles, MSD, Merck, IRL, CCBR, TCS, ICRI Global Research and other multinational companies as well as Indian companies recruited 3,500 students from ICRI. A large number of students have been placed in UK, Singapore and other locations abroad. In India students with MSc degrees have been placed at a starting salary between Rs 30,000 to 60,000 per month and the part time PG Diploma students have started with a salary between Rs 15,000-30,000 a month. Students placed in UK and Singapore are drawing a salary of Rs 21 lakh per annum.
According to Dr S K Gupta, dean & director general, Institute of Clinical Research (India), "This year again placements have gone well and the students have been placed before the course is completed. Over 22 students have been placed in the Drugs Control General of India's office. Also two of the senior students who had passed out three years ago have taken the position of Assistant Professors in NIPER to teach clinical research to the students in Hyderabad."
The ICRI placement team works towards informing the industry about the teaching methodology and ICRI courses. The ICRI Placement Division offers prospective employers a one-stop destination for their current and future relationships with the Institute.
"India has all the competitive advantages for conducting clinical trials. As the country is increasingly becoming a favoured destination for clinical trials, a gap analysis needs to be done to scale up all resources for clinical trials. This scale up is essential for India to cope with the large global clinical trial projects. ICRI aims to nurture and create an environment of learning, and implement international standards in the interests of Clinical Research students. This is to ensure India meets the global expectations as an emerging Clinical Research destination," said S R Dugal, chairman board of directors, ICRI.